Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011, 155(1):43-50 | DOI: 10.5507/bp.2011.017

NEW PHARMACOLOGICAL TREATMENTS FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PUMONARY DISEASE (COPD)

Nancy Elizabeth Laroccaa, Dolores Morenoa, Jenny Valentina Garmendiab, Juan Bautista De Sanctisb
a Department of Pathology and Physiopathology, Experimental Medicine Institute, Faculty of Medicine, Universidad Central de Venezuela
b Departments of Clinical and Basic Immunology, Institute of Immunology, Faculty of Medicine, Universidad Central de
Venezuela

Background: Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with abnormal inflammatory response of the lung to noxious particles or gasses. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed.

Methods and Results: A literature search using PubMed, Science Direct, EBSCO and free patents on line for the years 2000-2010.

Conclusions: Recent discoveries in the physiology and pathology of airways diseases have served to generate potential new drugs for the treatment of COPD patients. Several substances that block or activate specific pathways and receptors the aim of which is to decrease inflammation and increase airway obstruction reversibility are being used in different clinical protocols and hopefully will be available for patients in the near future.

Keywords: COPD, Pharmacological treatment, β agonists, Muscarinic receptor antagonists, Phosphodiesterase inhibitors, NKkb inhibitors, PI3K inhibitors

Received: October 2, 2010; Accepted: February 8, 2011; Published: March 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Larocca, N.E., Moreno, D., Garmendia, J.V., & De Sanctis, J.B. (2011). NEW PHARMACOLOGICAL TREATMENTS FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PUMONARY DISEASE (COPD). Biomedical papers, 155(1), 43-50. doi: 10.5507/bp.2011.017
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global Strategy for Diagnosis, Management and Prevention of COPD Updated 2009. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org.
    2. Cosio MG, Saetta M, Agusti A. Immunologic Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med 2009;360:244554. Go to original source... Go to PubMed...
    3. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008;8(3):18392. Go to original source... Go to PubMed...
    4. Curtis JL, Freeman CM, Hogg JC. The Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Insights from Recent Research. Proc Am Thorac Soc 2007;4:51221. Go to original source... Go to PubMed...
    5. Rennard SI. Chronic Obstructive Pulmonary Disease Linking Outcomes and Pathobiology of Disease Modification. Proc Am Thorac Soc 2006;3:276280. Go to original source... Go to PubMed...
    6. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:98294. Go to original source... Go to PubMed...
    7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S121. Go to PubMed...
    8. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:12561276. Go to original source...
    9. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:93246. Go to original source... Go to PubMed...
    10. Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6(8):6936. Go to original source... Go to PubMed...
    11. Cavalcante AG, de Bruin PF. The role of oxidative stress in COPD: current concepts and perspectives. J Bras Pneumol 2009;35(12):122737. Go to original source... Go to PubMed...
    12. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005;25:10841106. Go to original source... Go to PubMed...
    13. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010;19(5):3308. Go to original source... Go to PubMed...
    14. Buhl R, Farmer SG. Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2005;2:8393. Go to original source... Go to PubMed...
    15. Celli B, Goldstein R, Jardim J, Knobil K. Future perspectives in COPD. Respiratory Medicine 2005;99:S41S48. Go to original source... Go to PubMed...
    16. Hanani NA, Ambrosino N, Calverley P, Cazzola M, Donner CF, Make B. Treatments for COPD. Respiratory Medicine 2006;99:S28S40. Go to original source... Go to PubMed...
    17. Kolb M, Martin G, Medina M, Ask K, Gauldie J. Gene Therapy for Pulmonary Diseases. Chest 2006;130:879884. Go to original source... Go to PubMed...
    18. Meinke L, Chitkara R, Krishna G. Advances in the management of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007:8(1):2337. Go to original source... Go to PubMed...
    19. Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Internacional Journal of COPD 2006;1(4):409 423. Go to original source... Go to PubMed...
    20. Pelaia G, Vatrella A, Gallelli L, Renda T, Caputi M, Maselli R, Marsico SA. Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis 2006;1(3):321334. Go to original source... Go to PubMed...
    21. Seifart C, Vogelmeier C. Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerging Drugs 2009;14(1):181194. Go to original source... Go to PubMed...
    22. Cyr MC, Bauchesne MF, Lemiere C, Blais L. Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive lung disease. Br. J Clin Pharmacol 65(1),4550.
    23. Onoue S, Misaka S, Kwabata Y, Yamada S. New treatments for chronic obstructive pulmonary disease and viable formulation/ device options for inhalation therapy. Expert Opin Drug Deliv 2009;6(8):79381. Go to original source... Go to PubMed...
    24. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010;11:149. Go to original source... Go to PubMed...
    25. Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Current Opinion in Pharmacology 2008;8:300307. Go to original source... Go to PubMed...
    26. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. British Journal of Pharmacology 2008;155:291299. Go to original source... Go to PubMed...
    27. Currie GP, Butler CA, Anderson WJ, Skinner C. Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment. Br J Clin Pharmacol 2008;65(6):803810. Go to original source... Go to PubMed...
    28. Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010;4:14758.
    29. Gross NJ, Giembycz MA, Rennard SI. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010;7(2):14153. Go to original source... Go to PubMed...
    30. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacology & Therapeutics 2009;121:5568. Go to original source... Go to PubMed...
    31. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-B pathway in asthma and chronic obstructive pulmonary disease. Pharmacology & Therapeutics 2009;121:113. Go to original source... Go to PubMed...
    32. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010;138(5):120212. Go to original source... Go to PubMed...
    33. Matera MG, Calceta L, Cazzola M. TNF-a inhibitors in asthma and COPD: We must not throw the baby out with the bath water. Pulmonary Pharmacology & Therapeutics 2010;23:121128. Go to original source...
    34. Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010;4(1):1934. Go to original source... Go to PubMed...
    35. De Sanctis JB, Garmendia JV, Moreno D, Larocca N, Mijares M, Di Giulio C, Salazar-Bookaman M, Radzioch D. Pharmacological modulation of Th17. Rencent Patents in Allergy and Immunology 2009;3(2):14956 Go to original source...
    36. Chen ZH, Kim HP, Ryter SW, MK Choi A. Identifying targets for COPD treatment through gene expression analyses. International Journal of COPD 2008;3(3):359370. Go to original source...
    37. Wong S, Belvisi MG, Birrell MA. MMP/TIMP expression profiles in distinct lung disease models: implications for possible future therapies. Respir Res 2009;10:72. Go to original source... Go to PubMed...
    38. Séguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009;18(10):15051517. Go to original source... Go to PubMed...

    Return to the content